News
RNAC
21.17
-3.16%
-0.69
Weekly Report: what happened at RNAC last week (0506-0510)?
Weekly Report · 24m ago
Buy Rating Affirmed for Cartesian Therapeutics on Strong Clinical Progress and Strategic Expansion
TipRanks · 3d ago
Cartesian Therapeutics Price Target Maintained With a $54.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $54 Price Target
Benzinga · 3d ago
Buy Rating Affirmed on Cartesian Therapeutics with Promising Descartes-08 Therapy Outlook and Strong Financials
TipRanks · 4d ago
Cartesian Therapeutics, Inc. Quarterly Report for the Period Ended March 31, 2024
Press release · 4d ago
RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q1 2024
Cartyesian Therapeutics reported results for the first quarter of 2024. The company reported earnings per share of -$10.50 and revenue of $5.84 million. This was 367.20% better than the analyst estimate for the same period of time.
Investorplace · 4d ago
Cartesian Therapeutics Provides Business Updates at Industry Events
TipRanks · 5d ago
CARTESIAN THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Reuters · 5d ago
CARTESIAN THERAPEUTICS INC - CASH, CASH EQUIVALENTS, AND RESTRICTED EXPECTED TO SUPPORT PLANNED OPERATIONS INTO 2H 2026
Reuters · 5d ago
Press Release: Cartesian Therapeutics Reports -2-
This press release includes forward-looking statements. These statements include statements about the potential of Cartesian Therapeutics to fulfill unmet medical needs. The Company's actual results may differ from those expressed or implied by such statements. Factors that could affect the Company include the Company's ability to enroll patients in clinical trials and the risks related to its technology.
Dow Jones · 5d ago
Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Barchart · 5d ago
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, Inc. Is a clinical-stage company developing mRNA cell therapies for the treatment of autoimmune diseases. The company granted inducement awards to four new employees. Each of these employees has an option to purchase shares of the Company’s common stock.
Barchart · 6d ago
Weekly Report: what happened at RNAC last week (0429-0503)?
Weekly Report · 05/06 10:55
Weekly Report: what happened at RNAC last week (0422-0426)?
Weekly Report · 04/29 11:00
Cartesian: Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Press release · 04/26 22:11
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Nucor Corporation tumbled 6.5% to $179.20 on Tuesday. The company reported worse-than-expected quarterly financial results. Cyngn Inc. Shares jumped 100% after the company was chosen to supply John Deere with industrial automation. Pineapple Energy Inc. And Virgin Galactic Holdings, Inc. Were among the stocks moving in today's mid-day session.
Benzinga · 04/23 17:53
Cartesian Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/23 16:32
HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Adjusts Price Target To $54
Benzinga · 04/23 16:26
HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday
Shares of HealthStream, Inc. Rose sharply on Tuesday following upbeat quarterly results. The Nasdaq Composite gained over 200 points in Tuesday's session. Hibbett shares climbed 18.4% to $85.85 after the company agreed to be acquired by JD Sports Fashion.
Benzinga · 04/23 14:50
More
Webull provides a variety of real-time RNAC stock news. You can receive the latest news about Cartesian through multiple platforms. This information may help you make smarter investment decisions.
About RNAC
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.